Therapeutic immunization with an inactivated HIV-1 Immunogen plus antiretrovirals versus antiretroviral therapy alone in asymptomatic HIV-infected subjects

Vaccine

Volumn 22, Issue 23-24, 2004, Pages 2966-2973

  Fernandez Cruz, E ^a   Moreno, S ^b   Navarro, J ^a   Clotet, B ^c   Bouza, E ^a   Carbone, J ^a   Pena J M ^d   Perez Molina J ^a   Podzamczer, D ^e   Rubio, R ^f   Ocana I ^g   Pulido, F ^f   Viciana, P ^h   Maradona, J A ⁱ   Blazquez, R ^j   Barros, C ^k   Quereda, C ^b   Rodriguez Sainz, C ^a   Gil, J ^a   Abad, M L ^a   Diaz L ^a   Canto C ^a   Munoz M A ^a   Ferrer, E ^e   Jou, A ^c   Sirera, G ^c   Diaz M ^g   Lopez, F ^l   Gatell, J M ^m   Gonzalez Lahoz, J ⁿ   more..

^a HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^b HOSPITAL RAMÓN Y CAJAL   (Spain)

^c HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^d HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^e HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^f HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^g HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^h HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

ⁱ HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

^j HOSPITAL MORALES MESEGUER   (Spain)

^k HOSPITAL DE MÓSTOLES   (Spain)

^l Nufarm 21   (Spain)

^m HOSPITAL CLÍNIC   (Spain)

ⁿ INSTITUTO DE SALUD CARLOS III   (Spain)

more..

Author keywords

HIV 1 Immunogen; Therapeutic vaccination; Viral load

Indexed keywords

ANTIRETROVIRUS AGENT; DIDANOSINE; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; INDINAVIR; LAMIVUDINE; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; VIRUS RNA; ZIDOVUDINE;

ACTIVE IMMUNIZATION; ADULT; ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE ASSOCIATION; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION CONTROL; INFECTION RISK; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PATIENT; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEROTYPE; STATISTICAL SIGNIFICANCE; STRATIFICATION; VIROLOGY;

ADULT; AIDS VACCINES; ANTI-HIV AGENTS; CHEMOKINES; COMBINED MODALITY THERAPY; ENDPOINT DETERMINATION; FEMALE; HIV ENVELOPE PROTEIN GP120; HIV INFECTIONS; HIV-1; HUMANS; IMMUNITY, CELLULAR; INTERFERON TYPE II; LYMPHOPROLIFERATIVE DISORDERS; MALE; T-LYMPHOCYTES, HELPER-INDUCER; TH1 CELLS; VACCINES, INACTIVATED;

EID: 3843119977     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2004.03.040     Document Type: Article

References (30)

1. Finzi D., Blankson J., Siliciano J.D., Margolick J.B., Chadwick K., Pierson T., et al. Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Nat. Med. 5(5):1999;512-517
2. Condra J.H., Schleif W.A., Blahy O.M., et al. In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors. Nature. 374:1995;569-571
3. Shevitz A., Wanke C.A., Falutz J., Kotler D.P. Clinical perspectives on HIV-associated lipodystrophy syndrome: an update. AIDS. 15(15):2001;1917-1930
4. Valdez H., Connick E., Smith K.Y., Lederman M.M., Bosch R.J., Kim R.S., et al. Limited immune restoration after 3 years' suppression of HIV-1 replication in patients with moderately advanced disease. AIDS. 16(14):2002;1859-1866
5. Moss R.B., Giermakowska W.K., Savary J.R., Theofan G., Daigle A.E., Richieri S.P., et al. A primer on HIV type 1-specific immune function and REMUNE. AIDS Res. Hum. Retroviruses. 14(Suppl 2):1998;S167-S175
6. Turner J.L., Kostman J.R., Aquino A. The effects of an HIV-1 Immunogen (REMUNE) on viral load, CD4 cell counts and HIV-specific immunity in a double-blind, randomized, adjuvant-controlled subset study in HIV infected subjects regardless of concomitant antiviral drugs. HIV Med. 2(2):2001;68-77
7. Trauger R.J., Ferre F., Daigle A.E., Jensen F.C., Moss R.B., Mueller S.H., et al. Effect of immunization with inactivated gp120-depleted human immunodeficiency virus type 1 (HIV-1) Immunogen on HIV-1 immunity, viral DNA, and percentage of CD4 cells. J. Infect. Dis. 169(6):1994;1256-1264
8. Limsuwan A., Churdboonchart V., Moss R.B., Sirawaraporn W., Sutthent R., Smutharaks B., et al. Safety and Immunogenicity of REMUNE in HIV-infected Thai subjects. Vaccine. 16(2-3):1998;142-149
9. 6/L CD4 cell counts: a randomized controlled trial. JAMA. 284(17):2000;2193-2202
10. Choi D.J., Dube S., Spicer T.P., Slade H.B., Jensen F.C., Poiesz B.J. HIV type 1 isolate HZ321, the strain used to make a therapeutic HIV type 1 Immunogen, is intersubtype recombinant. AIDS Res. Hum. Retroviruses. 13(4):1997;357-361
11. LoGrippo G. Investigations of the use of beta-propiolactone in virus inactivation. Ann N Y Acad. Sci. 83:1960;578-594
12. Kitchen A.D., Mann G.F., Harrison J.F., Zuckerman A.J. Effect of gamma irradiation on the human immunodeficiency virus and human coagulation proteins. Vox. Sang. 56(4):1989;223-229
13. Wit F.W., van Leeuwen R., Weverling G.J., Jurriaans S., Nauta K., Steingrover R., et al. Outcome and predictors of failure of highly active antiretroviral therapy: one-year follow-up of a cohort of human immunodeficiency virus type 1-infected persons. J. Infect. Dis. 179(4):1999;790-798
14. Paredes R., Mocroft A., Kirk O., Lazzarin A., Barton S.E., van Lunzen J., et al. Predictors of virological success and ensuing failure in HIV-positive patients starting highly active antiretroviral therapy in Europe: results from the EuroSIDA study. Arch. Intern. Med. 160(8):2000;1123-1132
15. 3 CD4 T lymphocytes (AIDS Clinical Trials Group Protocol 137). J. Infect. Dis. 173(6):1996;1336-1346
16. Davey R.T. Jr., Murphy R.L., Graziano F.M., Boswell S.L., Pavia A.T., Cancio M., et al. Immunologic and virologic effects of subcutaneous interleukin 2 in combination with antiretroviral therapy: a randomized controlled trial. JAMA. 284(2):2000;183-189
17. Lange C.G., Lederman M.M., Medvik K., Asaad R., Wild M., Kalayjian R., et al. Nadir CD4+ T-cell count and numbers of CD28+ CD4+ T-cells predict functional responses to immunizations in chronic HIV-1 infection. AIDS. 17(14):2003;2015-2023
18. Gilbert P.B., DeGruttola V.G., Hudgens M.G., Self S.G., Hammer S.M., Corey L. What constitutes efficacy for a human immunodeficiency virus vaccine that ameliorates viremia: issues involving surrogate end points in phase 3 trials. J. Infect. Dis. 188(2):2003;179-193
19. Pontesilli O., Carotenuto P., Kerkhof-Garde S.R., Roos M.T., Keet I.P., Coutinho R.A., et al. Lymphoproliferative response to HIV type 1 p24 in long-term survivors of HIV type 1 infection is predictive of persistent AIDS-free infection. AIDS Res. Hum. Retroviruses. 15(11):1999;973-981
20. Rosenberg E.S., Billingsley J.M., Caliendo A.M., Boswell S.L., Sax P.E., Kalams S.A., et al. Vigorous HIV-1-specific CD4+ T cell responses associated with control of viremia. Science. 278(5342):1997;1447-1450
21. Redfield R.R., Birx D.L., Ketter N., Tramont E., Polonis V., Davis C., et al. A phase I evaluation of the safety and immunogenicity of vaccination with recombinant gp160 in patients with early human immunodeficiency virus infection. Military Medical Consortium for Applied Retroviral Research. N. Engl. J. Med. 324(24):1991;1677-1684
22. Sandstrom E., Wahren B. Therapeutic immunisation with recombinant gp160 in HIV-1 infection: a randomised double-blind placebo-controlled trial. Nordic VAC-04 Study Group. Lancet. 353(9166):1999;1735-1742
23. Robbins G.K., Addo M.M., Troung H., Rathod A., Habeeb K., Davis B., et al. Augmentation of HIV-1-specific T helper cell responses in chronic HIV-1 infection by therapeutic immunization. AIDS. 17:2003;1121-1126
24. Maino V.C., Suni M.A., Wormsley S.B., Carlo D.J., Wallace M.R., Moss R.B. Enhancement of HIV type 1 antigen-specific CD4+ T cell memory in subjects with chronic HIV type 1 infection receiving an HIV type 1 Immunogen. AIDS Res. Hum. Retroviruses. 16(6):2000;539-547
25. Moss R.B., Wallace M.R., Steigbigel R.T., Morrison S.A., Giermakowska W.K., Nardo C.J., et al. Predictors of HIV-specific lymphocyte proliferative immune responses induced by therapeutic vaccination. Clin. Exp. Immunol. 128(2):2002;359-364
26. Moss R.B., Webb E., Giermakowska W.K. HIV-1-specific CD4 helper function in persons with chronic HIV-1 infection on antiviral drug therapy as measured by ELISPOT after treatment with inactivated gp120-depleted HIV-1 in incomplete Freund's adjuvant. J. Acquir. Immune. Defic. Syndr. 24(3):2000;264-269
27. Ullum H., Cozzi Lepri A., Victor J., Aladdin H., Phillips A.N., Gerstoft J., et al. Production of beta-chemokines in human immunodeficiency virus (HIV) infection: evidence that high levels of macrophage inflammatory protein-1beta are associated with a decreased risk of HIV disease progression. J. Infect. Dis. 177(2):1998;331-336
28. Peters B.S. The basis for HIV immunotherapeutics vaccines. Vaccine. 20:2001;688-705
29. Lisziewicz J., Bakare N., Lori F. Therapeutic vaccination for future management of HIV/AIDS. Vaccine. 21:2003;620-623
30. Blower S, Moss RB, Fernandez-Cruz E. Calculating the potential epidemic-level impact of therapeutic vaccination on the San Francisco HIV epidemic. AIDScience (serial online) 2003;3(21). Available from URL: http://www/aidscience.org/Articles/AIDScience040.asp.